Veradermics reported a second quarter 2026 net loss of $23.5 million on zero revenue, as the company continues to focus on its clinical pipeline for pattern hair loss. The company significantly strengthened its liquidity through a $472 million follow-on offering and private placement in May 2026, extending its projected cash runway into 2030.
Key Highlights
- Cash and marketable securities reached $819.9 million as of June 30, 2026, more than double the estimated $390.8 million following secondary financing.
- Enrollment for the registration-directed Phase 2/3 Study '306' for female pattern hair loss is now complete, with topline data anticipated in the first half of 2027.
- Research and development expenses rose to $18.6 million from $14.3 million in the prior year period, reflecting increased clinical development activity for lead candidate VDPHL01.